4.4 Article

Incidence and risk factors of medical complications and direct medical costs after osteoporotic fracture among patients in China

Journal

ARCHIVES OF OSTEOPOROSIS
Volume 13, Issue 1, Pages -

Publisher

SPRINGER LONDON LTD
DOI: 10.1007/s11657-018-0429-5

Keywords

Osteoporotic fracture; Hip fracture; Vertebral fracture; Complications; Risk factors; Economic burden

Funding

  1. Lilly Suzhou Pharmaceutical Co. Ltd.

Ask authors/readers for more resources

We analyzed the incidence of medical complications after osteoporotic fractures and estimated its risk factors and cost impacts. Osteoporotic fractures can result in lots of serious medical complications, which is associated with patients' baseline characteristics such as patients' disease history and significantly increased patients' direct medical costs. Purpose The purpose of the study is to investigate the incidence and identify the risk factors of medical complications after osteoporotic fracture, and quantify patients' economic burden. Methods Data were obtained from the Tianjin Urban Employee Basic Medical Insurance database (2009-2014). Patients aged >= 50 years, had >= 1 diagnoses of hip or vertebral fracture between 2010 and 2012, and continuously enrolled from 12 months before to 24 months after the first identified fracture were included. The incidence of medical complications was estimated within 12 months before and after fracture. Direct medical costs were measured and compared between patients with at least one medical complication and without any medical complications. Logistic regression was applied to identify risk factors for any medical complications. Results Three thousand seven hundred nineteen patients were identified; 45.0% had hip fracture, and 56.2% had vertebral fracture. After osteoporotic fracture, the accumulative incidence of the most common medical complications including constipation (25.6%, RR 1.38 [1.28, 1.48]), stroke (25.2%, 1.16 [1.09, 1.24]), pneumonia (17.0%, 1.55 [1.40, 1.73]), urinary tract infection (16.3%, 1.23 [1.12, 1.36]), and arrhythmia (11.8%, 1.39 [1.23, 1.56]) was significantly higher than that before fracture. Advanced age; male sex; retirement status; diagnosis of hypertension, chronic heart disease, cerebrovascular disease, hemiplegia, or Parkinson's disease; and higher direct medical costs at baseline were significant predictors of complications. The all-cause direct medical cost during 24-month follow-up was $5665. Medical complications significantly increased patients' direct medical costs. Conclusions Osteoporotic fractures led to amount of medical complications, which significantly increased patients' economic burden. Complications correlate to various factors such as patients' disease history.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Health Care Sciences & Services

Comparative efficacy of dabrafenib plus trametinib versus treatment options for metastatic melanoma in first-line settings

Jing Wu, Jaydeep Das, Manik Kalra, Barbara Ratto

Summary: This study systematically reviewed the literature and found that dabrafenib + trametinib significantly prolongs survival in previously untreated melanoma patients, establishing it as one of the preferred treatment options.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)

Article Endocrinology & Metabolism

Direct Medical Costs of Incident Complications in Patients Newly Diagnosed With Type 2 Diabetes in China

Xiaoning He, Yawen Zhang, Yan Zhou, Chaohui Dong, Jing Wu

Summary: This study aimed to provide patient-level cost estimates of managing complications in newly diagnosed type 2 diabetes mellitus (T2DM) patients in China. After 7 years, a high percentage of patients at risk had developed nephropathy and neuropathy. The immediate and long-term costs for specific complications were examined, highlighting the substantial economic burden on the Chinese healthcare system.

DIABETES THERAPY (2021)

Article Environmental Sciences

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China

Tianfu Gao, Jia Liu, Jing Wu

Summary: The combination therapy of dabrafenib plus trametinib has been shown to increase patient life expectancy and quality-adjusted life years compared to vemurafenib, with a favorable cost-effectiveness profile in China.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

Article Environmental Sciences

Trends and Age-Period-Cohort Effects on the Prevalence, Incidence and Mortality of Hepatocellular Carcinoma from 2008 to 2017 in Tianjin, China

Chengyu Liu, Jing Wu, Zheng Chang

Summary: This study found that in recent years, the prevalence of hepatocellular carcinoma in China has been increasing annually, while the incidence remains stable and the mortality rate is decreasing. Age, period, and birth cohort have significant effects on the epidemiological trend of hepatocellular carcinoma.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

Article Pharmacology & Pharmacy

Heterogeneity in Price Elasticity of Medicine Demand in China: Moderate Effect From Economic Incentive and Quality Difference

Mingyue Zhao, Peng Nie, Jing Wu

Summary: This study examined the price elasticity of medicine demand in different therapeutic drug categories and types in China, finding variations in elasticity across drug categories and the impact of quality differences, unfair competition, and illegal rebates on price elasticity. The results showed that anti-tumor and CVD drugs had the least elasticity, while antimicrobial drugs had the most elasticity. This study highlights the role of disease type and drug quality in shaping price elasticity in the Chinese medicine market.

FRONTIERS IN PHARMACOLOGY (2021)

Article Economics

Population Norms for SF-6Dv2 and EQ-5D-5L in China

Shitong Xie, Jing Wu, Feng Xie

Summary: This study provides population norms for EQ-5D-5L and SF-6Dv2 among the Chinese general population, and identifies the impact of social-demographic characteristics and chronic conditions on utility values. These norms can serve as references for economic evaluations and healthcare decision-making in China.

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2022)

Article Public, Environmental & Occupational Health

Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China

Jing Wu, Chengyu Liu, Fengmei Wang

Summary: This study reveals that HCC patients covered by URRBMI may have worse survival than patients covered by UEBMI. Further efforts are warranted to understand healthcare disparities for patients covered by different basic medical insurance in China.

FRONTIERS IN PUBLIC HEALTH (2021)

Article Public, Environmental & Occupational Health

Incorporating future unrelated medical costs in cost-effectiveness analysis in China

Shan Jiang, Yitong Wang, Junwen Zhou, Yawen Jiang, Gordon Guo-En Liu, Jing Wu

Summary: The inclusion of future unrelated medical costs can improve the internal and external consistency of economic evaluation and the comparability of results between different jurisdictions. However, more research is needed to further explore this issue.

BMJ GLOBAL HEALTH (2021)

Article Economics

Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life

Dan Cai, Si Shi, Shan Jiang, Lei Si, Jing Wu, Yawen Jiang

Summary: The study aimed to estimate the cost-effective threshold (CET) of a quality-adjusted life year (QALY) in China as 1.5 times of GDP per capita, which should be benchmarked for future ICER-based coverage decisions.

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2022)

Article Health Care Sciences & Services

Discrete choice experiment with duration versus time trade-off: a comparison of test-retest reliability of health utility elicitation approaches in SF-6Dv2 valuation

Shitong Xie, Jing Wu, Gang Chen

Summary: This study evaluates and compares the test-retest reliability of discrete choice experiments with duration and time trade-off in the Chinese SF-6Dv2 valuation study. The results show that both approaches have relatively stable consistency at the individual and aggregate level.

QUALITY OF LIFE RESEARCH (2022)

Article Economics

Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model

Jia Liu, Xiaoning He, Jing Wu

Summary: The study evaluated the cost-effectiveness of Budesonide/glycopyrrolate/formoterol fumarate (BGF) compared to LAMA/LABA therapies for patients with moderate to very severe COPD in China. Results showed that BGF treatment led to fewer exacerbations and was a cost-effective option, improving outcomes compared to the composite comparator.

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2022)

Article Public, Environmental & Occupational Health

The Impact of Hyperkalemia on Mortality and Healthcare Resource Utilization Among Patients With Chronic Kidney Disease: A Matched Cohort Study in China

Jiahui Zhang, Xiaoning He, Jing Wu

Summary: In Chinese chronic kidney disease patients, hyperkalemia is associated with substantially increased clinical and economic burdens that are driven by the short period following the hyperkalemia events, which strengthens calls for sufficient supervision and management of serum potassium.

FRONTIERS IN PUBLIC HEALTH (2022)

Article Health Care Sciences & Services

Policy Updates on Access to and Affordability of Innovative Medicines in China

Gordon G. Liu, Jing Wu, Xiaoning He, Yawen Jiang

Summary: This review explores the initiatives taken by the Chinese government to improve access to innovative medicines through regulatory and reimbursement measures, resulting in accelerated drug launches and expanded coverage. However, standardized and transparent evidence appraisal processes are still needed.

VALUE IN HEALTH REGIONAL ISSUES (2022)

Letter Psychiatry

Confidence of evidence should be considered in ranking of treatments in the network meta-analysis

Shitong Xie, Ying Zhu, Xiaoqin Wang, Jing Wu, Qi Wang

LANCET PSYCHIATRY (2022)

Article Economics

Do Rural Residents in China Understand EQ-5D-5L as Intended? Evidence From a Qualitative Study

Fan Yang, Shan Jiang, Xiao-ning He, Hong-chao Li, Hong-yan Wu, Tian-tian Zhang, Jing Wu

Summary: The content validity of EQ-5D-5L among rural Chinese was studied, revealing that participants found the domains of 'mobility', 'self-care', and 'usual activities' easy to understand, but reported confusion in 'pain/discomfort' and 'anxiety/depression'. Suggestions were made to reduce response levels and provide alternative wordings for 'slight'.

PHARMACOECONOMICS-OPEN (2021)

No Data Available